Vir Biotechnology Inc (NASDAQ:VIR) has a beta value of 0.66 and has seen 0.54 million shares traded in the recent trading session. The VIR stock price is -35.94% off its 52-week high price of $14.45 and 38.29% above the 52-week low of $6.56. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.35 million shares traded. The 3-month trading volume is 2.21 million shares.
The consensus among analysts is that Vir Biotechnology Inc (VIR) is Buy stock at the moment, with a recommendation rating of 1.56. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 3 out of 10 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.87.
Vir Biotechnology Inc (NASDAQ:VIR) trade information
Over the past 30 days, the shares of Vir Biotechnology Inc (NASDAQ:VIR) have changed 44.82%. Short interest in the company has seen 6.55 million shares shorted with days to cover at 4.51.
Wall Street analysts have a consensus price target for the stock at $24, which means that the shares’ value could jump 55.71% from the levels at last check today. The projected low price target is $20.0 while the price target rests at a high of $28.0. In that case, then, we find that the latest price level in today’s session is -163.41% off the targeted high while a plunge would see the stock gain -88.15% from the levels at last check today.
Vir Biotechnology Inc (VIR) estimates and forecasts
Figures show that Vir Biotechnology Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -0.28% over the past 6 months, with this year growth rate of 14.60%, compared to 16.40% for the industry. Revenue growth from the last financial year stood is estimated to be -12.77%.
5 analysts offering their estimates for the company have set an average revenue estimate of 9.37M for the current quarter. 4 have an estimated revenue figure of 13.66M for the next ending quarter. Year-ago sales stood 16.79M and 56.38M respectively for this quarter and the next, and analysts expect sales will shrink by -44.19% for the current quarter and -12.77% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -34.12% over the past 5 years. Earnings growth for 2025 is a modest 15.42% while over the next 5 years, the company’s earnings are expected to increase by 9.14%.
VIR Dividends
Vir Biotechnology Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Vir Biotechnology Inc (NASDAQ:VIR)’s Major holders
Insiders own 11.90% of the company shares, while shares held by institutions stand at 74.53% with a share float percentage of 84.60%. Investors are also buoyed by the number of investors in a company, with Vir Biotechnology Inc having a total of 289.0 institutions that hold shares in the company. The top two institutional holders are SB INVESTMENT ADVISERS (UK) LTD with over 16.68 million shares worth more than $148.49 million. As of 2024-06-30, SB INVESTMENT ADVISERS (UK) LTD held 12.3329% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 16.43 million shares as of 2024-06-30. The firm’s total holdings are worth over $146.26 million and represent 12.1482% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are iShares Core S&P Smallcap ETF and Vanguard Total Stock Market Index Fund. As of Nov 30, 2024 , the former fund manager holds about 4.28% shares in the company for having 5.9 shares of worth $62.66 million while later fund manager owns 3.46 shares of worth $36.76 million as of Sep 30, 2024 , which makes it owner of about 2.51% of company’s outstanding stock.
